Optimizing adjuvant treatment in HR+/HER2- early breast cancer

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

WATCH NOW: Optimizing Early Breast Cancer Outcomes in the Community SettingПодробнее

Optimizing adjuvant endocrine therapy for early Breast CancerПодробнее

Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trialsПодробнее

Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Th...Подробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic TherapyПодробнее

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее